Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.4005
Abstract: Importance Chimeric and murine anti-GD2 antibodies are active against neuroblastoma, but the development of neutralizing antibodies can compromise efficacy. To decrease immunogenicity, hu3F8, a humanized anti-GD2 antibody, was constructed. Objective To find the maximum-tolerated dose… read more here.
Keywords: trial; anti gd2; antibody; cycle ... See more keywords
A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors
Sign Up to like & getrecommendations! Published in 2020 at "mAbs"
DOI: 10.1080/19420862.2020.1773751
Abstract: ABSTRACT Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m2 daily for 4 days in children with recurrent/refractory neuroblastoma.… read more here.
Keywords: humanized anti; anti gd2; schedule; patients osteosarcoma ... See more keywords
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO
Sign Up to like & getrecommendations! Published in 2017 at "OncoImmunology"
DOI: 10.1080/2162402x.2017.1343775
Abstract: ABSTRACT Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC). Strategies to further enhance the efficacy are important and… read more here.
Keywords: anti gd2; cho; blockade; ch14 cho ... See more keywords
First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002488
Abstract: Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells,… read more here.
Keywords: sarcoma; gd2; like sarcoma; metastatic ewing ... See more keywords
Antibody‐Dependent Cellular Cytotoxicity of iPS Cell‐Derived Natural Killer T Cells by Anti‐GD2 mAb for Neuroblastoma
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Science"
DOI: 10.1111/cas.70008
Abstract: While antibody‐dependent cellular cytotoxicity (ADCC) by anti‐disialoganglioside GD2 monoclonal antibody (mAb) has succeeded in increasing the survival rate of high‐risk patients with neuroblastoma, approximately 40%–50% of patients die from the disease. Recently, we developed induced… read more here.
Keywords: cytotoxicity; anti gd2; ips nkt; nkt cells ... See more keywords
Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004399
Abstract: Background Anti-GD2 monoclonal antibody immunotherapy has significantly improved the overall survival rate for high-risk neuroblastoma patients. However, 40% of patients fail to respond or develop resistance to treatment, and the molecular mechanisms by which this… read more here.
Keywords: derived sevs; immunotherapy; anti gd2; neuroblastoma ... See more keywords
Abstract 5115: Novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+ breast cancer stem-like cells
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5115
Abstract: Background: Breast cancer stem-like cells (BCSCs) are reported to be a major contributing factor for tumor growth and chemotherapy resistance in triple-negative breast cancer (TNBC). We reported that the disialoganglioside GD2 is highly expressed on… read more here.
Keywords: cell; gd2; breast cancer; anti gd2 ... See more keywords
Abstract 5122: Modulating anti-GD2 immunotherapy via dual DFMO and TGF-β inhibition in neuroblastoma
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-5122
Abstract: Neuroblastoma (NB) is an often-lethal childhood solid tumor. Anti-GD2 immunotherapy improves survival but not all responses are durable. Transforming growth factor-beta (TGFβ) has been implicated in solid tumor immunoresistance. High-risk NBs harbor activated MYC or… read more here.
Keywords: anti gd2; tgf; tumor; galunisertib ... See more keywords
Abstract ND08: M3554, a novel anti-GD2 antibody drug conjugate
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-nd08
Abstract: The glycosphingolipid GD2 is a cell membrane component of a limited number of normal tissues including nerve cells, melanocytes or lymphocytes. However, in some tumor types as neuroblastoma, osteosarcoma, glioma, or soft tissue sarcoma, GD2… read more here.
Keywords: gd2 antibody; anti gd2; m3554 novel; novel anti ... See more keywords
Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.10543
Abstract: 10543Background: NB is a rare cancer but represents the most common extracranial solid tumor of childhood. Most HR-NB patients present with or develop metastatic disease typically in bone or bone m... read more here.
Keywords: new generation; generation anti; gd2 monoclonal; naxitamab new ... See more keywords
Spinal nerve roots contrast enhancement following anti-GD2 antibody therapy in neuroblastoma
Sign Up to like & getrecommendations! Published in 2018 at "Neurology"
DOI: 10.1212/wnl.0000000000005483
Abstract: A 2-year-old boy with grade IV neuroblastoma presented with acute neurogenic bladder and hyposthenia after 2 weeks of treatment with anti-ganglioside-GD2 antibody (GD2-Ab). Spinal MRI findings are shown in the figure. On nerve conduction studies,… read more here.
Keywords: anti gd2; contrast enhancement; gd2 antibody; spinal nerve ... See more keywords